Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31542016 | 1.00 | KDR (0.54) | KDRNPFFR2PDK1HSD11B1HTR3E | |
| SCHEMBL10656533 | 0.86 | KDR (0.56) | KDRNPFFR2PDK1HSD11B1HTR3E | |
| SCHEMBL10532934 | 0.85 | KMO (0.43) | KDRPDK1NOTUM | |
| SCHEMBL375961 | 0.85 | TSHR (0.59) | KDRNPFFR2PDK1HSD11B1HTR3E | |
| SCHEMBL31542017 | 0.84 | NOTUM (0.42) | KDRNPFFR2HSD11B1MAPTNOTUM | |
| SCHEMBL2680326 | 0.84 | NOTUM (0.42) | KDRNPFFR2HSD11B1MAPTNOTUM | |
| Hydrochloric Acid SCHEMBL6369011 | 0.83 | TSHR (0.57) | KDRNPFFR2PDK1HSD11B1HTR3E | |
| SCHEMBL31144967 | 0.83 | NPFFR2 (0.58) | KDRNPFFR2PDK1HSD11B1HTR3E | |
| SCHEMBL1086197 | 0.83 | NPFFR2 (0.58) | KDRNPFFR2PDK1HSD11B1HTR3E | |
| SCHEMBL76697 | 0.83 | NPFFR2 (0.58) | KDRNPFFR2PDK1HSD11B1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3403651-B1 | ISOCORYDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | LANZHOU INST CHEMICAL PHYSICS CAS (CN) | 2019-10-30 | — | — | EP | claimed |
| US-20180334448-A1 | Isocorydine derivatives, preparation method and use thereof | LANZHOU INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2018-11-22 | — | — | US | claimed |
| EP-3403651-A1 | ISOCORYDINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | Lanzhou Institute Of Chemical Physics Chinese Academy of Sciences (CN) | 2018-11-21 | — | — | EP | claimed |
| CN-116535358-A | Benzamide derivative with sulfur-containing cyano pyrazole structure, preparation method and application thereof | 西北农林科技大学 | 2023-08-04 | — | — | CN | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| EP-3938362-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-01-19 | — | — | EP | disclosed |
| CN-113710667-A | Fused cyclic pyrimidinone derivatives for the treatment of HBV infection or HBV induced diseases | 爱尔兰詹森科学公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20060079526-A1 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1628967-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-01 | — | — | EP | disclosed |
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2005000833-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2005-01-06 | — | — | WO | disclosed |
| EP-0279698-A2 | Pesticidal compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-08-24 | — | — | EP | disclosed |
| US-4425282-A | Preparation of 3-(arylvinyl)-2,2-dimethyl-cyclopropane-1-carboxylic acid esters and new intermediate therefor | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-10 | — | — | US | disclosed |
| EP-0018533-B1 | SUBSTITUTED PENTANE (OR PENTENE) CARBOXYLIC ACIDS AND THEIR DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF 3-(ARYLVINYL)-2,2-DIMETHYL-CYCLOPROPANE-1-CARBOXYLATES | BAYER AG (DE) | 1983-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KDR 56/4885NPFFR2 824/4885PDK1 4078/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | KDR 2362/4885NPFFR2 4399/4885PDK1 445/4885 |
| US-20180334448-A1 | Isocorydine derivatives, preparation method and use thereof | CCND2, CCND3, IDH3A | KDR 4635/4885NPFFR2 392/4885PDK1 2968/4885 |
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | KDR 4445/4885NPFFR2 3227/4885PDK1 818/4885 |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | KDR 999/4885NPFFR2 1509/4885PDK1 2503/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | KDR 4229/4885NPFFR2 2498/4885PDK1 637/4885 |
| US-20060079526-A1 | Heterocyclic compounds and methods of use | AADAC, NISCH, PAICS | KDR 4380/4885NPFFR2 2269/4885PDK1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.